184 related articles for article (PubMed ID: 9130644)
41. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
[TBL] [Abstract][Full Text] [Related]
42. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
43. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes.
Vukmanovic-Stejic M; Vyas B; Gorak-Stolinska P; Noble A; Kemeny DM
Blood; 2000 Jan; 95(1):231-40. PubMed ID: 10607707
[TBL] [Abstract][Full Text] [Related]
44. Altered CD40 ligand induction in tolerant T lymphocytes.
Bowen F; Haluskey J; Quill H
Eur J Immunol; 1995 Oct; 25(10):2830-4. PubMed ID: 7589079
[TBL] [Abstract][Full Text] [Related]
45. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
[TBL] [Abstract][Full Text] [Related]
46. B cell differentiation induced by helper T cell membranes: evidence for sequential isotype switching and a requirement for lymphokines during proliferation.
Hodgkin PD; Castle BE; Kehry MR
Eur J Immunol; 1994 Jan; 24(1):239-46. PubMed ID: 8020562
[TBL] [Abstract][Full Text] [Related]
47. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
48. Human immunodeficiency virus-1 infection protects against a Tc1-to-Tc2 shift in CD8(+) T cells.
Gulzar N; Diker B; Balasubramanian S; Jiang JQ; Copeland KF
Hum Immunol; 2011 Nov; 72(11):995-1000. PubMed ID: 21920400
[TBL] [Abstract][Full Text] [Related]
49. Regulation of murine B cell growth and differentiation by CD30 ligand.
Shanebeck KD; Maliszewski CR; Kennedy MK; Picha KS; Smith CA; Goodwin RG; Grabstein KH
Eur J Immunol; 1995 Aug; 25(8):2147-53. PubMed ID: 7664777
[TBL] [Abstract][Full Text] [Related]
50. CD40 ligand-independent B cell activation revealed by CD40 ligand-deficient T cell clones: evidence for distinct activation requirements for antibody formation and B cell proliferation.
Lane P; Burdet C; McConnell F; Lanzavecchia A; Padovan E
Eur J Immunol; 1995 Jun; 25(6):1788-93. PubMed ID: 7615009
[TBL] [Abstract][Full Text] [Related]
51. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
Helmich BK; Dutton RW
J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
[TBL] [Abstract][Full Text] [Related]
52. Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses.
Ozdemirli M; El-Khatib M; Foote LC; Wang JK; Marshak-Rothstein A; Rothstein TL; Ju ST
Eur J Immunol; 1996 Feb; 26(2):415-9. PubMed ID: 8617312
[TBL] [Abstract][Full Text] [Related]
53. [Detection of peripheral blood Th1/Th2 and Tc1/Tc2 subsets in patients with condyloma acuminatum and its significance].
Zhu N; Cheng H; Zhu KJ; Zhang X; Xu Y; Jiang DH
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Jun; 23(3):229-31. PubMed ID: 20104787
[TBL] [Abstract][Full Text] [Related]
54. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
55. T lymphocytes from the normal human peritoneum contain high frequencies of Th2-type CD8+ T cells.
Birkhofer A; Rehbock J; Fricke H
Eur J Immunol; 1996 Apr; 26(4):957-60. PubMed ID: 8625996
[TBL] [Abstract][Full Text] [Related]
56. Interleukin (IL) 4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines.
Sad S; Mosmann TR
J Exp Med; 1995 Nov; 182(5):1505-15. PubMed ID: 7595220
[TBL] [Abstract][Full Text] [Related]
57. Type II pneumocyte-CD8+ T-cell interactions. Relationship between target cell cytotoxicity and activation.
Zhao MQ; Amir MK; Rice WR; Enelow RI
Am J Respir Cell Mol Biol; 2001 Sep; 25(3):362-9. PubMed ID: 11588015
[TBL] [Abstract][Full Text] [Related]
58. CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells.
Johnson-Léger C; Christensen J; Klaus GG
Int Immunol; 1998 Aug; 10(8):1083-91. PubMed ID: 9723694
[TBL] [Abstract][Full Text] [Related]
59. CD8(+) T cells with distinct cytokine-producing features and low cytotoxic activity in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps.
Ma J; Shi LL; Deng YK; Wang H; Cao PP; Long XB; Zhang XH; Liu Y; Zeng M; Liu Z
Clin Exp Allergy; 2016 Sep; 46(9):1162-75. PubMed ID: 27176491
[TBL] [Abstract][Full Text] [Related]
60. T-dependent activation of resting B cells mediated by concanavalin A.
Ratcliffe MJ; Julius MH
Eur J Immunol; 1984 Mar; 14(3):280-3. PubMed ID: 6231188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
